BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24038408)

  • 1. Xerostomia in patients treated for oropharyngeal carcinoma: comparing linear accelerator-based intensity-modulated radiation therapy with helical tomotherapy.
    Fortin I; Fortin B; Lambert L; Clavel S; Alizadeh M; Filion EJ; Soulières D; Bélair M; Guertin L; Nguyen-Tan PF
    Head Neck; 2014 Sep; 36(9):1343-8. PubMed ID: 24038408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of xerostomia incidence after three-dimensional conformal radiation therapy and contralateral superficial lobe parotid-sparing intensity-modulated radiotherapy for oropharyngeal and hypopharyngeal cancer.
    Kawamoto T; Nihei K; Nakajima Y; Kito S; Sasai K; Karasawa K
    Auris Nasus Larynx; 2018 Oct; 45(5):1073-1079. PubMed ID: 29397249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Helical tomotherapy for head and neck squamous cell carcinoma: dosimetric comparison with linear accelerator-based step-and-shoot IMRT.
    Murthy V; Master Z; Gupta T; Ghosh-Laskar S; Budrukkar A; Phurailatpam R; Agarwal J
    J Cancer Res Ther; 2010; 6(2):194-8. PubMed ID: 20622367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience.
    de Arruda FF; Puri DR; Zhung J; Narayana A; Wolden S; Hunt M; Stambuk H; Pfister D; Kraus D; Shaha A; Shah J; Lee NY
    Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):363-73. PubMed ID: 15925451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensity-modulated radiation therapy (IMRT) dosimetry of the head and neck: a comparison of treatment plans using linear accelerator-based IMRT and helical tomotherapy.
    Sheng K; Molloy JA; Read PW
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):917-23. PubMed ID: 16751074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can dose reduction to one parotid gland prevent xerostomia?--A feasibility study for locally advanced head and neck cancer patients treated with intensity-modulated radiotherapy.
    Anand AK; Jain J; Negi PS; Chaudhoory AR; Sinha SN; Choudhury PS; Kumar R; Munjal RK
    Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):497-504. PubMed ID: 16909975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recovery of Salivary Function: Contralateral Parotid-sparing Intensity-modulated Radiotherapy versus Bilateral Superficial Lobe Parotid-sparing Intensity-modulated Radiotherapy.
    Miah AB; Gulliford SL; Morden J; Newbold KL; Bhide SA; Zaidi SH; Hall E; Harrington KJ; Nutting CM
    Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e69-e76. PubMed ID: 26994893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using a reduced spot size for intensity-modulated proton therapy potentially improves salivary gland-sparing in oropharyngeal cancer.
    van de Water TA; Lomax AJ; Bijl HP; Schilstra C; Hug EB; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e313-9. PubMed ID: 21708427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of salivary gland dosimetry on post-IMRT recovery of saliva output and xerostomia grade for head-and-neck cancer patients treated with or without contralateral submandibular gland sparing: a longitudinal study.
    Wang ZH; Yan C; Zhang ZY; Zhang CP; Hu HS; Tu WY; Kirwan J; Mendenhall WM
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1479-87. PubMed ID: 20934262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of parotid gland irradiation in the development of severe hyposalivation (xerostomia) after intensity-modulated radiation therapy for head and neck cancer: Temporal patterns, risk factors, and testing the QUANTEC guidelines.
    Owosho AA; Thor M; Oh JH; Riaz N; Tsai CJ; Rosenberg H; Varthis S; Yom SH; Huryn JM; Lee NY; Deasy JO; Estilo CL
    J Craniomaxillofac Surg; 2017 Apr; 45(4):595-600. PubMed ID: 28256385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sparing bilateral neck level IB in oropharyngeal carcinoma and xerostomia outcomes.
    Tam M; Riaz N; Kannarunimit D; Peña AP; Schupak KD; Gelblum DY; Wolden SL; Rao S; Lee NY
    Am J Clin Oncol; 2015 Aug; 38(4):343-7. PubMed ID: 26208401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent chemoradiotherapy with helical tomotherapy for oropharyngeal cancer: a preliminary result.
    Shueng PW; Wu LJ; Chen SY; Hsiao CH; Tien HJ; Cheng PW; Kuo YS; Chen YJ; Chen CA; Hsieh PY; Hsieh CH
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):715-21. PubMed ID: 19879069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential of intensity-modulated proton radiotherapy to reduce swallowing dysfunction in the treatment of head and neck cancer: A planning comparative study.
    van der Laan HP; van de Water TA; van Herpt HE; Christianen ME; Bijl HP; Korevaar EW; Rasch CR; van 't Veld AA; van der Schaaf A; Schilstra C; Langendijk JA;
    Acta Oncol; 2013 Apr; 52(3):561-9. PubMed ID: 22708528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of the initial volume of parotid glands in xerostomia for patients with head and neck cancers treated with IMRT.
    Nishimura Y; Nakamatsu K; Shibata T; Kanamori S; Koike R; Okumura M; Suzuki M
    Jpn J Clin Oncol; 2005 Jul; 35(7):375-9. PubMed ID: 15976068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3D-conformal-intensity modulated radiotherapy with compensators for head and neck cancer: clinical results of normal tissue sparing.
    Wendt TG; Abbasi-Senger N; Salz H; Pinquart I; Koscielny S; Przetak SM; Wiezorek T
    Radiat Oncol; 2006 Jun; 1():18. PubMed ID: 16790059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes and xerostomia after postoperative radiotherapy for oral and oropharyngeal carcinoma.
    Wang ZH; Yan C; Zhang ZY; Zhang CP; Hu HS; Tu WY; Kirwan J; Mendenhall WM
    Head Neck; 2014 Oct; 36(10):1467-73. PubMed ID: 23996878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient- and therapy-related factors associated with the incidence of xerostomia in nasopharyngeal carcinoma patients receiving parotid-sparing helical tomotherapy.
    Lee TF; Liou MH; Ting HM; Chang L; Lee HY; Wan Leung S; Huang CJ; Chao PJ
    Sci Rep; 2015 Aug; 5():13165. PubMed ID: 26289304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Submandibular gland-sparing radiation therapy for locally advanced oropharyngeal squamous cell carcinoma: patterns of failure and xerostomia outcomes.
    Gensheimer MF; Liao JJ; Garden AS; Laramore GE; Parvathaneni U
    Radiat Oncol; 2014 Nov; 9():255. PubMed ID: 25424729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosimetric Predictors of Patient-Reported Xerostomia and Dysphagia With Deintensified Chemoradiation Therapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma.
    Chera BS; Fried D; Price A; Amdur RJ; Mendenhall W; Lu C; Das S; Sheets N; Marks L; Mavroidis P
    Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1022-1027. PubMed ID: 28721884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing xerostomia after chemo-IMRT for head-and-neck cancer: beyond sparing the parotid glands.
    Little M; Schipper M; Feng FY; Vineberg K; Cornwall C; Murdoch-Kinch CA; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):1007-14. PubMed ID: 22056067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.